Query Drug：Olaparib
Query Time：2025-03-10 13:13:19
*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
About the Drug
Olaparib (Lynparza) is a PARP inhibitor used to treat types of breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, fallopian tube cancer, or peritoneal cancer. Olaparib works by blocking a protein called PARP which helps cancer cells repair themselves, blocking PARP causes the cancer cells die.
Olaparib is often used if your cancer has a specific genetic marker, including BRAC1, BRCA2, HRR, and HER2-negative. Your doctor will test you for this gene.
Olaparib is a tablet that is usually taken twice daily, with or without food.
Lynparza was first FDA-approved in 2014 for advanced ovarian cancer.
Olaparib is FDA-approved to treat specific types of cancer.
Related Diseases
Extra Information on Drug and Diseases
Drug olaparib
RXCUI: 1597582
May Treat
Similar Drugs
[may_treat] Ovarian Neoplasms
Source MEDRT
[Physiological Effect] Decreased DNA Integrity
Source: MEDRT
[Physiological Effect] Decreased Reverse Transcription to DNA
Source: MEDRT
[Physiological Effect] Cellular Growth Phase Reduction
Source: MEDRT
[Mechanism of Action] Poly(ADP-Ribose) Polymerase Inhibitors
Source DAILYMED
[Mechanism of Action] Poly(ADP-Ribose) Polymerase Inhibitors
Source FDASPL
[Mechanism of Action] Poly(ADP-Ribose) Polymerase Inhibitors
Source MEDRT
[Phamacological Category] Poly(ADP-Ribose) Polymerase Inhibitor
Source FDASPL
[Phamacological Category] Poly(ADP-Ribose) Polymerase Inhibitor
Source DAILYMED
Orange Book
[Last update] 2024-12-25
Labelers
Olaparib's Innovator is ASTRAZENECA PHARMACEUTICALS LP
Drug Products
The unique dosage forms from the innovator include：1. TABLET;ORAL；2. CAPSULE;ORAL.
| Index | Route | Brand Name | Labeler | Approval Date | Dosage |
| 1 | CAPSULE;ORAL | LYNPARZA | ASTRAZENECA PHARMACEUTICALS LP | Dec 19, 2014 | 50MG |
| 2 | TABLET;ORAL | LYNPARZA | ASTRAZENECA PHARMACEUTICALS LP | Aug 17, 2017 | 100MG |
| 3 | TABLET;ORAL | LYNPARZA | ASTRAZENECA PHARMACEUTICALS LP | Aug 17, 2017 | 150MG |
Drug Patents
This drug still has 12 effective patents.
| Patent Number | Submission Date | Expiration Date | Drug Substance Patent? | Drug Product Patent? |
| 8143241 | Jan 15, 2015 | Aug 12, 2027 |
|
|
| 8859562 | Jan 15, 2015 | Aug 4, 2031 |
|
|
| 8247416 | Jan 15, 2015 | Sep 24, 2028 | Y |
|
| 8475842 | Sep 15, 2017 | Dec 31, 2029 |
| Y |
| 7449464 | Sep 15, 2017 | Sep 8, 2027 | Y | Y |
| 8071579 | Jun 18, 2020 | Aug 12, 2027 |
|
|
| 11633396 | May 19, 2023 | Oct 7, 2029 |
| Y |
| 11970530 | May 28, 2024 | Oct 25, 2041 |
|
|
| 11975001 | Jun 3, 2024 | Oct 7, 2029 |
| Y |
| 12048695 | Aug 23, 2024 | Oct 7, 2029 |
| Y |
| 12144810 | Dec 10, 2024 | Oct 7, 2029 |
| Y |
| 12178816 | Jan 24, 2025 | Oct 7, 2029 |
| Y |
Related Company's Product Pipelines
The innovator ASTRAZENECA PHARMACEUTICALS LP's portolio contains products with the following 27 API(s)： ISOSORBIDE DINITRATE, AMITRIPTYLINE HYDROCHLORIDE, QUETIAPINE FUMARATE, SELUMETINIB SULFATE, FELODIPINE, ZOLMITRIPTAN, TAMOXIFEN CITRATE, TOCAINIDE HYDROCHLORIDE, FULVESTRANT, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE SODIUM, ATENOLOL, FORMOTEROL FUMARATE; GLYCOPYRROLATE, SODIUM ZIRCONIUM CYCLOSILICATE, TICAGRELOR, BUDESONIDE; FORMOTEROL FUMARATE, BUDESONIDE, OLAPARIB, ALBUTEROL SULFATE; BUDESONIDE, CAPIVASERTIB, OMEPRAZOLE, ROFLUMILAST, OMEPRAZOLE MAGNESIUM, ENALAPRIL MALEATE; FELODIPINE, OSIMERTINIB MESYLATE, OMEGA-3-CARBOXYLIC ACIDS, GEFITINIB
The above products are related to 105 diseases： Angina Pectoris, Esophageal Spasm, Diffuse, Coronary Disease, Cyanosis, Gastroesophageal Reflux, Poisoning, Heart Failure, Depressive Disorder, Pain, Bipolar Disorder, Schizophrenia, Depressive Disorder, Major, Psychotic Disorders, Autistic Disorder, Neurofibromatosis 1, Angina Pectoris, Variant, Hypertension, Migraine Disorders, Breast Neoplasms, Gynecomastia, Carcinoma, Ductal, Breast, Puberty, Precocious, Pancreatic Neoplasms, Breast Neoplasms, Helicobacter Infections, Esophagitis, Zollinger-Ellison Syndrome, Stomach Ulcer, Heartburn, Gastroesophageal Reflux, Duodenal Ulcer, Helicobacter Infections, Esophagitis, Zollinger-Ellison Syndrome, Stomach Ulcer, Heartburn, Gastroesophageal Reflux, Duodenal Ulcer, Angina Pectoris, Atrial Fibrillation, Ventricular Fibrillation, Hypertension, Atrial Flutter, Tachycardia, Ventricular, Myocardial Infarction, Tachycardia, Supraventricular, Heart Failure, Asthma, Bronchial Spasm, Asthma, Exercise-Induced, Abnormalities, Drug-Induced, Respiratory Tract Diseases, Peptic Ulcer, Hyperhidrosis, Hyperkalemia, Myocardial Infarction, Stroke, Coronary Thrombosis, Nasal Polyps, Asthma, Rhinitis, Allergic, Perennial, Inflammatory Bowel Diseases, Asthma, Bronchial Spasm, Asthma, Exercise-Induced, Nasal Polyps, Asthma, Rhinitis, Allergic, Perennial, Inflammatory Bowel Diseases, Ovarian Neoplasms, Asthma, Bronchial Spasm, Asthma, Exercise-Induced, Nasal Polyps, Asthma, Rhinitis, Allergic, Perennial, Inflammatory Bowel Diseases, Breast Neoplasms, Helicobacter Infections, Esophagitis, Zollinger-Ellison Syndrome, Stomach Ulcer, Heartburn, Gastroesophageal Reflux, Duodenal Ulcer, Pulmonary Disease, Chronic Obstructive, Helicobacter Infections, Esophagitis, Zollinger-Ellison Syndrome, Stomach Ulcer, Heartburn, Gastroesophageal Reflux, Duodenal Ulcer, Arthritis, Rheumatoid, Hypertension, Malignant, Diabetic Nephropathies, Hypertrophy, Left Ventricular, Ventricular Dysfunction, Left, Edema, Bartter Syndrome, Heart Failure, Angina Pectoris, Variant, Hypertension, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung
